#WFH2018 — SPK-9001 Reduces Bleeding Rates by 98% in Hemophilia B Patients, Phase 1/2 Trial Shows
SPK-9001, an investigational gene therapy being developed by Spark Therapeutics and Pfizer, continues to demonstrate great potential to treat hemophilia B patients in an ongoing Phase 1/2 clinical trial. The latest results showed that the annualized bleeding rates of all treated patients were reduced by 98%. In…